The bacterial enterotoxins, cholera toxin and the heat labile toxin of
E. coil, are well known adjuvants for mucosal immune response. Their
common A chain mediates the toxigenic mechanism by causing ADP ribosyl
ation of G proteins and subsequent elevation of cAMP in target cells.
A large IgA and IgG antibody response to admired protein antigen (Ag)
is the hallmark of these adjuvants and is clearly associated with the
A chain activity. Expansion of Ag-specific B and T cells, alteration o
f T cell cytokine production, and changes in regulatory T cells have b
een reported as adjuvant mechanisms. The B chain derivatives of these
toxins can also weakly enhance immune response, especially if covalent
ly associated with Ag and used for nasophyrangeal immunization. Import
antly, these toxins or their B chain derivatives can alter the normal
immune regulation that produces oral tolerance. This indicates that th
ey modulate mechanisms operative between the mucosal and systemic immu
ne systems. There are some discrepancies between in vitro models of CT
or LT activity and in vivo manifestations of their adjuvant activitie
s. interpretation of current data regarding in vivo mechanism is hampe
red by an incomplete understanding of how mucosal B and T cells can in
teract with systemic lymphoid tissue and vice versa. More important, t
here is no clear understanding of the early effects of the toxins on t
he local (and draining) mucosal lymphoid tissues. This is especially t
rue in the critical areas of antigen presentation, T and B cell activa
tion, and cytokine production.